Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 3rd International Workshop on High-risk Multiple Myeloma (iwHRMM 2026) took place in Charleston, SC, on 21-23 October 2026. This meeting brought together the world’s leading clinical researchers to discuss the latest advances in high-risk multiple myeloma.
iwHRMM 2026
The 3rd International Workshop on High-risk Multiple Myeloma
21–23 October 2026 | Charleston, SC
The 3rd International Workshop on High-risk Multiple Myeloma (iwHRMM 2026) took place in Charleston, SC, on 21-23 October 2026. This meeting brought together the world’s leading clinical researchers to discuss the latest advances in high-risk multiple myeloma.
Roundtable discussions
View all
Expert interviews
View all
Defining high-risk multiple myeloma
Circulating and extramedullary disease
NSD2/MMSET disease subset
When standard risk isn’t: identifying functional high-risk myeloma
What we know about antigen loss
New approaches for high risk – lab and clinic
MAF/MAFB disease
Designing studies in high-risk MM
Treatment sequencing in high-risk MM
The evolving role of MRD-guided treatment decisions
Defining high-risk multiple myeloma
Plasma cell identity escape as hallmark of high risk myeloma
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon!
Defining functional high risk myeloma
Moritz Binder Mayo Clinic, Rochester, MN, United States
Coming soon!
Ultra-high-risk MM – update from OPTIMUM
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Coming soon!
Defining a high-risk microenvironment
Faith Davies NYU Langone Health, New York City, NY, United States
Coming soon!
Genomic instability underlies high-risk multiple myeloma
Gareth Morgan NYU Langone Health, New York City, NY, United States
Coming soon!
Circulating and extramedullary disease
Non-invasive bone marrow surrogates for high-risk multiple myeloma
Juan José Garcés Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon!
Fragmentomic and genomic profiling of cell-free DNA to track tumor burden in multiple myeloma
Dory Abelman Dana-Farber Cancer Institute, Boston, MA, United States
Coming soon!
Uncovering of high-risk features of extra- and paramedullary disease by spatial profiling
Niels Wienhold Heidelberg University, Heidelberg, Germany
Coming soon!
Paramedullary/extramedullary myeloma dataset
Kylee Maclachlan Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon!
Transcriptional profile of EMD and PCL
Saurabh Zanwar Mayo Clinic, Rochester, MN, United States
Coming soon!
Tackling extramedullary disease with immunotherapy
Darren Pan Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Coming soon!
NSD2/MMSET disease subset
Targeting NSD2 and NSD2-dependent biology in t(4;14) MM
Benjamin Barwick Winship Cancer Institute of Emory University, Atlanta, GA, United States
Coming soon!
Apoptotic dependencies in t(4;14) myeloma
Lawrence Boise Emory Winship Cancer Institute, Atlanta, GA, United States
Coming soon!
The crossroads of t(4;14) breakpoints, NSD2 isoforms and patient outcome
Jonathan Keats TGen, Phoenix, AZ, United States
Coming soon!
Preclinical and translational data on a novel NSD2 inhibitor
Erin Flynt K36 Therapeutics, Cambridge, MA, United States
Coming soon!
When standard risk isn’t: identifying functional high-risk myeloma
Rethinking standard risk: biology of high-risk t(11;14) MM
Linda Baughn Mayo Clinic, Rochester, MN, United States
Coming soon!
Identifying tumor-reactive T cells: toward immune-based risk stratification in myeloma
Simone Minnie University of California, San Francisco, CA, United States
Coming soon!
When does the immune system lose control? Host immune fitness as a determinant of high-risk myeloma
Erin Meermeier Mayo Clinic, Phoenix, AZ, United States
Coming soon!
Transcriptional profiling and functional high-risk
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Coming soon!
What we know about antigen loss
Mechanisms of BCMA and GPRC5D antigen escape
Holly Lee University of Calgary's Cumming School of Medicine, Calgary, Canada
Coming soon!
Detection and quantifying antigen loss – clinical implications of antigen loss
Ajay Nooka Winship Cancer Institute of Emory University, Atlanta, GA, United States
Coming soon!
Myeloma cell “identity” and immunotherapy failure
Ross Firestone Memorial Sloan Kettering Cancer Center, Montvlae, NJ, United States
Coming soon!
Beyond the antigen: immune determinants of response and resistance to CAR T cells and T cell engagers
Tarek Mouhieddine Mount Sinai Medical Center, New York City, NY, United States
Coming soon!
New approaches for high risk – lab and clinic
BCMA targeting in vivo CART in the clinic
Simon Harrison Peter MacCallum Cancer Centre, Melbourne, Australia
Coming soon!
Engineering strategies for in vivo CAR deliveries
Karlo Perica Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon!
BMS 986453, a dual targeting BCMA x GPRC5D CAR-T for the treatment of RRMM
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
Coming soon!
Harnessing ferroptosis for t(4;14) multiple myeloma therapy
Mala Shanmugam Winship Cancer Institute of Emory University, Atlanta, GA, United States
Coming soon!
MAF/MAFB disease
Should dysregulation of all MAF transcription factors be considered equal?
Jonathan Keats TGen, Phoenix, AZ, United States
Coming soon!
PDX models show the presence of convergent evolution high-risk subclones in patient samples
Brian Walker Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon!
Designing studies in high-risk MM
Overcoming “classical” HRMM by TCE-combinations: currently available data and impact on study design
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
Coming soon!
How can we do trials for newly diagnosed high risk myeloma: trial designs and challenges
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Coming soon!
Timing of immunotherapy in randomized trials for high-risk myeloma
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
Coming soon!
MMRC Horizon Two – an adaptive platform trial for high risk newly diagnosed multiple myeloma
Hearn Jay Cho Icahn School of Medicine at Mount Sinai Hospital, New York City, NY, United States
Coming soon!
Treatment sequencing in high-risk MM
Early T-cell engaging therapy vs ASCT in high-risk NDMM and PCL
Shonali Midha Dana-Farber Cancer Institute, Boston, MA, United States
Coming soon!
Single versus multi-antigen targeting in high-risk MM
Thomas Martin University of California, San Francisco, CA, United States
Coming soon!
Using ‘n’ of 1 for hypothesis generation in high-risk MM
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming soon!
Immunotherapeutic sequencing for newly diagnosed primary refractory high-risk myeloma
Ajay Nooka Winship Cancer Institute of Emory University, Atlanta, GA, United States
Coming soon!
The evolving role of MRD-guided treatment decisions
Reaching and sustaining MRD negativity in patients with high-risk multiple myeloma
Douglas Sborov Huntsman Cancer Institute, Salt Lake City, UT, United States
Coming soon!
MRD-guided and genomics-informed treatment adaptation in myeloma
Benjamin Diamond Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon!
Novel MRD testing through telomere analysis
Sandra Mazzoni Cleveland Clinic, Cleveland, OH, United States
Coming soon!
The iwHRMM 2026 meeting was supported by:
